NASDAQ · Biotechnology

XENE (XENE) Stock

$65.78 +0.55% NASDAQ: XENE Healthcare

Valuation

MetricValue
Price$65.78
Market Cap$6.36B
P/E Ratio-12.40
P/B Ratio7.33
P/S Ratio533.39
EPS (TTM)$-4.36
52-Week High$70.96
52-Week Low$30.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-59.45%
ROA-35.23%
ROCE-64.09%
Gross Margin-4662.50%
Operating Margin-4662.50%
Net Margin-4325.00%
Debt/Equity0.01
Current Ratio13.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$18.0M$9.0M$0$0$8.0M
Operating Profit$-79.0M$-129.0M$-214.0M$-279.0M$-373.0M
Net Profit$-79.0M$-125.0M$-182.0M$-234.0M$-346.0M
EPS$-1.77$-2.06$-2.73$-3.01$-4.36
Op Margin-428.4%-1368.9%——-4974.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$572.0M$754.0M$965.0M$798.0M$982.0M
Total Liabilities$22.0M$33.0M$37.0M$43.0M$400.0M
Cash$176.0M$57.0M$149.0M$143.0M$199.0M
Borrowings$8.0M$10.0M$11.0M$9.0M$8.0M

Latest News

Why Wall Street Is Growing More Cautious on Biohaven (BHVN) Insider Monkey · Jul 6, 2026 Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why Zacks · Jun 23, 2026 Assessing Xenon Pharmaceuticals (XENE) Valuation After Recent Share Price Pullback And Modest Undervaluation Estimate Simply Wall St. · Jun 11, 2026 UPGUYS Founders Mat Rezaei and Ramin Behzadi Named 2026 EY Entrepreneur Of The Year® Pacific Region Finalists as Canada's Leading TRT Platform Scales Nationwide CNW Group · Jun 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-70.0M$-98.0M$-145.0M$-181.0M$-279.0M
Investing Cash Flow$-249.0M$-299.0M$-123.0M$162.0M$217.0M
Financing Cash Flow$0$1.0M$0$0$0
Net Cash Flow$131.0M$-118.0M$91.0M$-6.0M$56.0M
Free Cash Flow$-72.0M$-101.0M$-151.0M$-184.0M$-280.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-7.20%
Quick Ratio27.79
Interest Coverage—
Return 1Y111.94%
Return 3Y80.33%
Return 5Y266.90%

Ownership

Insiders Held0.13%
Institutions Held107.49%
Institutions Float Held107.63%
Institutional HolderSharesReport Date
FMR, LLC10,818,4912026-03-31
Avoro Capital Advisors LLC5,777,7772026-03-31
Blackrock Inc.5,640,1182026-03-31
Wellington Management Group, LLP4,829,6412026-03-31
Driehaus Capital Management, LLC4,491,6532026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPGAscentage Pharma Group International $20.18 +4.89% -9.87 $1.88B 0.00%
APGE $134.19 +0.06% -16.89 $8.30B 0.00%
CELC $92.49 +5.44% -91.68 $4.51B 0.00%
CGON $72.17 -1.84% -26.72 $6.37B 0.00%
CNTACentessa Pharmaceuticals plc $40.50 +0.00% -22.75 $6.27B 0.00%

About XENE

XENE is led by CEO Ian C. Mortimer, employs 316 people, headquartered in Burnaby, CA, publicly traded since 2014.

XENE stock trades at $65.78 with a market capitalization of $6.36B. The stock is valued at a price-to-earnings (P/E) ratio of -12.40, price-to-book of 7.33, price-to-sales of 533.39. Over the past 52 weeks the stock has ranged between $30.00 and $70.96, and currently trades 7.3% below its 52-week high.

On profitability, XENE generates a return on equity (ROE) of -59.45%, return on capital employed of -64.09%, an operating margin of -4662.50%, a net profit margin of -4325.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides